ClinicalTrials.gg
RecruitingNCT07457580Updated Nov 9, 2026

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

An observational study in Type 1 Diabetes, sponsored by Sanofi. Recruiting at 16 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Sanofi · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 9, 2026Site recruiting status changed2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
60
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.

Started
2026
with 1 other
Observational
6 of 67
4 open now
Registered
67th of 67
by date

Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 67th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Diabetes Mellitus, Type 1 by Sanofi, or all of them as a file.
02

Study summary

This study is a multi-country, multi-center retrospective observational cohort study based on secondary data collected via chart review, with the aim of describing patient characteristics (including relevant comorbidities), monitoring and treatment practices related to Type 1 diabetes mellitus (T1D) progression, and time to T1D progression in participants who received teplizumab as part of Managed Access Programs (MAPs). This study design was chosen in order to gain rapid insight into the current use of teplizumab in clinical practice and the characteristics of patients who received the treatment.

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with Stage 2 T1D who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment. Approximately 60 participants, in approximately 15 sites across at least 5 countries will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient written or electronic or assent (for patients \< 18 years old) according to local regulations or appropriate informed consent waivers prior to any study related activity.
  • Patient received ≥ 1 day of teplizumab treatment as part of MAPs.

Exclusion criteria

Exclusion Criteria:

  • Participation in an interventional clinical study on the index date. Participation in an interventional clinical study is defined as initiating the product/procedure or control under investigation. An interventional clinical study is a study that requires deviation from standard clinical practice by following a study protocol.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Stage 2 Type 1 Diabetes (T1D) who received Teplizumab

    Drug: Teplizumab

Interventions

  • This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

06

What researchers measure

Primary outcomes

  1. Participant demographics at teplizumab initiation

    Age, sex at birth, height, weight, Body mass index (BMI), body surface area

    Time frame: At Day 1 (first dose of teplizumab)

  2. Participants' family history of T1D and autoimmune diseases

    First- and second-degree relatives with T1D

    Time frame: At Day 1 (first dose of teplizumab)

  3. Presence of T1D susceptibility genes

    Genetic risk score

    Time frame: At Day 1 (first dose of teplizumab)

  4. Presence of T1D susceptibility genes

    Human Leukocyte Antigen (HLA)-haplotype

    Time frame: At Day 1 (first dose of teplizumab)

  5. Participants' medical history

    Date of stage 1 confirmation, date of dysglycemia confirmation

    Time frame: From 6 months prior to the first dose of teplizumab (teplizumab initiation) (or the earliest date of all data contributing to Stage 2 T1D diagnosis, whichever is earlier) up to medical records abstraction date, approximately 3-4 years

Secondary outcomes

  1. Time from Stage 1 T1D confirmation to Stage 2 confirmation

    Only participants with a date of Stage 1 T1D confirmation will be included in this analysis.

    Time frame: From the date of Stage 1 T1D confirmation to date of first assessment of dysglycemia or positive autoantibody test up to date of first dose of teplizumab (teplizumab initiation), approximately 6 months to a year

  2. Time from Stage 2 T1D confirmation to teplizumab initiation

    Time frame: From the date of first assessment of dysglycemia or positive autoantibody test up to date of first dose of teplizumab (teplizumab initiation), approximately 6 months to a year

  3. Assessment of blood glucose test results: Glycated hemoglobin (HbA1c)

    Time frame: At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)

  4. Assessment of blood glucose test results: Fasting Plasma Glucose (FPG)

    Time frame: At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)

  5. Assessment of blood glucose test results: Oral Glucose Tolerance Test (OGTT)

    Time frame: At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)

  6. Assessment of blood glucose test results: Random Plasma Glucose (PG)

    Time frame: At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)

  7. Assessment of blood glucose test results: Post-prandial Glucose (PPG)

    Time frame: At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)

  8. Assessment of blood glucose test results: Continuous glucose monitoring (CGM)

    Time frame: At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)

  9. Assessment of C-peptide test results

    Time frame: At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)

  10. Assessment of autoantibody test results

    Anti-GAD65, IAA, Anti-IA-2, ICA, Anti-ZnT8

    Time frame: At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)

  11. Proportion of participants who complete teplizumab treatment course

    Time frame: At Day 1 (first dose of teplizumab) until end of follow-up, up to 24 months

  12. Proportion of participants using insulin during the study period

    Time frame: At Day 1 (first dose of teplizumab) until end of follow-up, up to 24 months

  13. Proportion of participants using other glucose lowering therapies during the study period

    Time frame: At Day 1 (first dose of teplizumab) until end of follow-up, up to 24 months

07

Study locations

2 of 16 sites recruiting
  • Investigational Site Number: 0560001
    Leuven, 3000, Belgium
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 2500001
    Bron, 69677, France
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 2500003
    Paris, 75014, France
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 2500002
    Paris, 75015, France
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 2760003
    Augsburg, 86156, Germany
    Recruiting
  • Investigational Site Number: 2760002
    Frankfurt, 60596, Germany
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 2760001
    Hanover, 30173, Germany
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 2760004
    Munich, 80939, Germany
    Recruiting
  • Investigational Site Number: 3800001
    Ancona, 60123, Italy
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 3800003
    Palermo, 90127, Italy
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 3800002
    Verona, 37126, Italy
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 7240001
    Madrid, 28034, Spain
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 7240002
    Madrid, 28046, Spain
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 7240003
    Zaragoza, 50009, Spain
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 8260001
    Birmingham, B4 6NH, United Kingdom
    Completed

    Not enrolling at this site.

  • Investigational Site Number: 8260002
    London, E1 1BB, United Kingdom
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Mar 9, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. 14 sites changed recruiting status (14 now completed)
Show 14 sites
  • Investigational Site Number: 0560001 · Leuven, BelgiumRecruiting→Completed
  • Investigational Site Number: 2500001 · Bron, FranceRecruiting→Completed
  • Investigational Site Number: 2500003 · Paris, FranceRecruiting→Completed
  • Investigational Site Number: 2500002 · Paris, FranceRecruiting→Completed
  • Investigational Site Number: 2760002 · Frankfurt, GermanyRecruiting→Completed
  • Investigational Site Number: 2760001 · Hanover, GermanyRecruiting→Completed
  • Investigational Site Number: 3800001 · Ancona, ItalyRecruiting→Completed
  • Investigational Site Number: 3800003 · Palermo, ItalyRecruiting→Completed
  • Investigational Site Number: 3800002 · Verona, ItalyRecruiting→Completed
  • Investigational Site Number: 7240001 · Madrid, SpainRecruiting→Completed
  • Investigational Site Number: 7240002 · Madrid, SpainRecruiting→Completed
  • Investigational Site Number: 7240003 · Zaragoza, SpainRecruiting→Completed
  • Investigational Site Number: 8260001 · Birmingham, United KingdomRecruiting→Completed
  • Investigational Site Number: 8260002 · London, United KingdomRecruiting→Completed
Show 2 added (2 Germany)
  • Investigational Site Number: 2760003 · Augsburg, Germany
  • Investigational Site Number: 2760004 · Munich, Germany
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    2 sites added. 14 sites changed recruiting status (14 now completed)
    Show 14 sites
    • Investigational Site Number: 0560001 · Leuven, BelgiumRecruiting→Completed
    • Investigational Site Number: 2500001 · Bron, FranceRecruiting→Completed
    • Investigational Site Number: 2500003 · Paris, FranceRecruiting→Completed
    • Investigational Site Number: 2500002 · Paris, FranceRecruiting→Completed
    • Investigational Site Number: 2760002 · Frankfurt, GermanyRecruiting→Completed
    • Investigational Site Number: 2760001 · Hanover, GermanyRecruiting→Completed
    • Investigational Site Number: 3800001 · Ancona, ItalyRecruiting→Completed
    • Investigational Site Number: 3800003 · Palermo, ItalyRecruiting→Completed
    • Investigational Site Number: 3800002 · Verona, ItalyRecruiting→Completed
    • Investigational Site Number: 7240001 · Madrid, SpainRecruiting→Completed
    • Investigational Site Number: 7240002 · Madrid, SpainRecruiting→Completed
    • Investigational Site Number: 7240003 · Zaragoza, SpainRecruiting→Completed
    • Investigational Site Number: 8260001 · Birmingham, United KingdomRecruiting→Completed
    • Investigational Site Number: 8260002 · London, United KingdomRecruiting→Completed
    Show 2 added (2 Germany)
    • Investigational Site Number: 2760003 · Augsburg, Germany
    • Investigational Site Number: 2760004 · Munich, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07457580
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Mar 16, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 9, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. Option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion